Provider review
telos rx Review: The Seller That Answers "Will This Heal My Injury?" With "We Cannot Say That"
telos rx sells the deepest peptide catalog of any company we've reviewed and is the most carefully written storefront among them. Everything is "studied for" rather than claimed, every page says the preparation is not FDA-approved, and both pharmacies are named. What that cannot fix is the catalog under it: 5-Amino-1MQ has no trial record, GHK-Cu’s only trial is a topical gel against an injection, and the CJC-1295 study was terminated.
Correction, August 2026
This review previously said: “Sermorelin has no human trial record at all.”
That was wrong. The search behind it had been restricted to a paper's title and abstract, and the trial literature calls this molecule GHRH(1-29)-NH2 rather than sermorelin — so the restriction hid the trials rather than finding none. The three control molecules run alongside it were all findable by title and abstract, so they confirmed nothing.
It now says: PubMed's own filter returns 19 randomized controlled trials of sermorelin, published between 1986 and 2005, on growth-hormone stimulation and on growth in children with growth hormone deficiency. None of them measured the outcomes it is sold for here, and all 19 predate the 2007 rule that made trial registration mandatory, which is why the registry is empty.
telos rx is the best-written storefront in this market and it is selling some of the thinnest evidence in it, which is a genuinely unusual combination. Almost every claim is hedged as "studied for" rather than asserted; every product page says the preparation is not FDA-approved; both pharmacies are named with street addresses; the clinical entity is named separately; and the company volunteers that one of its own suppliers cannot make sterile compounds. Its BPC-157 FAQ answers "will this heal my injury?" with "We cannot say that." Its PT-141 page is the only one in this entire review series that states the evidence is in women with HSDD rather than selling it to men for performance. Underneath all of that, the catalog is the least-evidenced on the site: sermorelin's only trials are pituitary pharmacology from 1986-2005, 5-Amino-1MQ has no human trial record at all, GHK-Cu's only trial is a topical gel while the product is an injection, the CJC-1295 study was terminated, and TB-500's trial is measuring something else entirely. "Studied for" is doing a great deal of honest work — and a reader should understand that for most of this catalog it means studied in cells, in animals, or in a trial that has not finished enrolling.
Worth trusting if
- You want the pharmacy named, because telos rx names both — VialsRX in Houston and Jungle Jim's in Ohio — with addresses and phone numbers.
- You want a seller that will say no, because its BPC-157 FAQ answers "will this heal my injury?" with "we cannot say that".
- You are buying PT-141 and want the evidence stated straight, because this page says the studies are in women with low sexual desire.
Be skeptical if
- You are paying month to month, because every headline figure here is a plan-length rate and no monthly figure is published.
- You are buying GHK-Cu as an injection, because the only registered trial is a topical gel for skin wounds.
- You want 5-Amino-1MQ on human evidence, because it has no registry record and no randomized trial at all.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens telosrx.com. A link is not a recommendation to take anything.
Provenance
What telos rx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- BPC-157 Injection — "As low as $116 per month", with $189 struck through when read on 2026-08-10. The low figure is a plan-length rate — telos rx states "Your price depends on plan length" — and no month-to-month figure is published. Re-checked 2026-08-25: the listed figures have moved and no struck-through price appears on the options page.
- BPC-157 / TB-500 Stack — "As low as $133 per month", again a plan-length rate.
- CJC-1295 / Ipamorelin — Published only inside the intake; no figure is rendered on the product page.
- GHK-Cu Injection (10 mg/mL) — Published only inside the intake; no figure is rendered on the product page.
- MOTS-C — "As low as $116 per month", a plan-length rate.
- Sermorelin — "As low as $125 per month", with $299 struck through, read 2026-08-10. Re-checked 2026-08-25: the options page now lists different figures and shows no struck-through reference price.
- NAD+ Nasal Spray — "As low as $116 per month", with $249 struck through, read 2026-08-10. Re-checked 2026-08-25: the options page now lists different figures and shows no struck-through reference price.
- PT-141 — "Less than $5 a day*", where the asterisk resolves on the page to "*Based on the 12-month plan" — a disclosed footnote, which is more than most sellers manage.
- 5-Amino-1MQ Injection (2 mg/mL) — Published only inside the intake; no figure is rendered on the product page.
- Semax / Selank Nootropic Stack — Published only inside the intake; no figure is rendered on the product page.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 10 products reviewed here. The evidence belongs to the molecule, not to telos rx.
8
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from telos rx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
BPC-157 InjectionBPC-157 · Compounded (503A)Claim matches the trials
“BPC-157 is a research peptide studied for the body's natural repair pathways. It is taken as a small injection under the skin. telos rx compounds it through a licensed US pharmacy, and it is not FDA-approved. A licensed provider reviews your intake and decides whether it fits you. Approval is not guaranteed, and individual results vary. […] Will BPC-157 heal a specific injury or condition? We cannot say that. BPC-157 is not approved to treat, cure, or prevent any disease or injury, and we make no promises about outcomes.”
Read on the telos rx site, August 2026
Phase 2 only
What the trials show for BPC-157
- NCT07437547 BPC-HAMSTR — Phase 2, recruiting, n=120. BPC 157 for acute hamstring muscle strain repair. Recruiting, not reporting — no result exists yet.
- NCT02637284 — Phase 1, unknown status, n=42. A 42-participant safety and pharmacokinetics trial of the BPC-157 product Bepecin. Its registry status is UNKNOWN — the sponsor has not updated it — which is weaker than completed.
Graded as matching because telos rx claims exactly what the record supports and no more: BPC-157 is "studied for" repair pathways, and it is — one phase 2 trial is recruiting for acute hamstring strain, and a 42-person phase 1 safety study exists whose registry status is Unknown. It states the preparation is not FDA-approved, that approval is not guaranteed, and that results vary. Then its FAQ refuses the sale it could most easily make: asked whether BPC-157 will heal a specific injury, it answers "We cannot say that… we make no promises about outcomes." What a reader should still hold onto: no completed human efficacy trial of BPC-157 exists. "Studied for" is accurate and is not the same as "shown to", and the phase 2 trial that might one day settle it is still enrolling.1,2
BPC-157 / TB-500 StackTB-500 (thymosin beta-4 fragment 17-23) with BPC-157 · Compounded (503A)Claim reaches past the trials
“BPC-157 and TB-500 are research peptides studied for the body's repair pathways. telos rx compounds them through a licensed US pharmacy, and neither is FDA-approved. A licensed provider reviews your intake and decides whether it fits you.”
Read on the telos rx site, August 2026
Phase 2 only
- NCT07487363 TBRIDGE-CV — Phase 1/Phase 2, recruiting, n=80. TB-500 for CARDIOVASCULAR BIOMARKERS in stable atherosclerotic disease — not tissue repair, not athletic recovery. Recruiting, not reporting.
The hedging is the same as the BPC-157 page and is fair, but the stack page carries the repair framing across to TB-500, and there the registry points somewhere else entirely. The only trial naming TB-500 as an intervention is TBRIDGE-CV, which is measuring CARDIOVASCULAR BIOMARKERS in adults with stable atherosclerotic disease — a different endpoint, a different population, and still recruiting. There is no registered study of TB-500 for tissue repair or recovery in humans. Graded as reaching past the trials rather than unsupported because "studied for" remains literally true — TB-500 is being studied, just not for this.3
CJC-1295 / IpamorelinCJC-1295 and ipamorelin · Compounded (503A)Claim reaches past the trials
“CJC-1295 is a GHRH analog. Ipamorelin is a selective growth hormone secretagogue. Together they are studied for prompting your pituitary to release growth hormone in its own natural rhythm. telos rx compounds both as research peptides, and neither is FDA-approved. A licensed provider reviews your intake, and approval is not guaranteed. Individual results vary.”
Read on the telos rx site, August 2026
Phase 2 only
- NCT00267527 — Phase 2, terminated, n=120. TERMINATED, not completed. It studied CJC-1295 in HIV patients with visceral obesity — a specific clinical population, and the trial did not run to completion.
The pharmacology is stated correctly and modestly — CJC-1295 is a GHRH analog, ipamorelin is a selective secretagogue, and prompting pulsatile release really is the mechanism. The gap is what "studied" is resting on. The only registry record naming CJC-1295 as an intervention is a phase 2 trial that was TERMINATED, enrolling 120 HIV patients with visceral obesity. A terminated trial in a specific clinical population is a thin foundation for an anti-aging purchase by a healthy adult, and the page does not mention either the termination or the population. Read live from the registry on 10 August 2026.4
GHK-Cu Injection (10 mg/mL)GHK-Cu · Compounded (503A)Claim reaches past the trials
“You already make GHK-Cu. Levels tend to drop as you get older. It is a copper-binding peptide studied for cell signaling linked to skin remodeling, collagen turnover, and tissue repair pathways. telos rx offers it as a compounded research peptide from a licensed US pharmacy. It is not FDA-approved. A licensed provider reviews your intake and decides whether it fits you.”
Read on the telos rx site, August 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 CuHeal — Phase 2, recruiting, n=60. TOPICAL GHK-Cu GEL for acute skin wound healing. telos rx sells a subcutaneous INJECTION. Recruiting, not reporting.
Everything about the molecule is stated accurately: GHK-Cu is endogenous, levels do decline with age, and it is a copper-binding peptide involved in the signaling described. The problem is the route, and it is not a technicality. The single registry record for GHK-Cu is CuHeal — a phase 2 trial of a TOPICAL GEL for acute skin wounds, still recruiting. telos rx dispenses a 10 mg/mL subcutaneous injection. A gel applied to a wound and an injection into subcutaneous tissue are different exposures with different distribution, and a trial of one is not evidence for the other. Nothing on the page marks that difference.5
MOTS-CMOTS-c · Compounded (503A)Claim matches the trials
“MOTS-C is a peptide encoded inside mitochondrial DNA, where it acts as a signal. It is studied for how cells sense energy, and for metabolic balance, cellular stress response, and pathways tied to exercise and healthy aging. telos rx compounds it as a research peptide through a licensed US pharmacy. It is not FDA-approved, and a licensed provider reviews your intake. Approval is not guaranteed.”
Read on the telos rx site, August 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity. Recruiting, not reporting.
This is the best-calibrated peptide page we've reviewed. MOTS-c genuinely is encoded in mitochondrial DNA and genuinely does act as a signaling peptide; the registry holds one phase 2 trial, MOTS-MET, studying insulin sensitivity in prediabetes — which is squarely inside "metabolic balance" and "how cells sense energy". telos rx claims the molecule is studied for those things, and it is. It does not promise a metabolic outcome, where a competitor selling the same molecule headlines "Make your metabolism work harder, even without changing your diet". The trial is still recruiting, so no result exists — a reader should not read "studied for" as "shown to".6
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“Sermorelin — GHRH peptide that stimulates your own growth hormone for recovery, lean muscle, and sleep.”
Read on the telos rx site, August 2026
No trial for this use
What the trials show for Sermorelin
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six searches were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies returned are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified diagnostic "GHRH". PubMed is the opposite: searched WITHOUT restricting to title and abstract, its own filter returns 19 randomized controlled trials, published 1986-2005 under the name GHRH(1-29)-NH2, on growth-hormone stimulation and growth in children with GH deficiency. Restricted to title and abstract the same query returns 0 — a restriction that hides the trials rather than proving none exist. None of the 19 measured anything telos rx sells sermorelin for, and all of them predate the 2007 rule that made registration mandatory, which is why the registry is empty. The registry searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
The sermorelin nav description is the one place telos rx drops its own hedge. Everywhere else the formula is "studied for"; here it is "stimulates your own growth hormone FOR recovery, lean muscle, and sleep" — three outcomes stated as purposes the drug serves, for the one molecule in this catalog with no human trial record of any kind under any name. It is still far milder than competitors selling the same peptide on a month-by-month schedule of results, and the product page keeps the not-FDA-approved disclosure. But the hedge that makes the rest of this site defensible is missing from the line that sells it.7,8
NAD+ Nasal SprayNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Intranasal NAD+ for cellular energy, mental clarity, and recovery.”
Read on the telos rx site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed randomized trial of intranasal NAD+ in humans, and no registered study measures nose-to-brain delivery of NAD+ or a cognitive endpoint from it. A PubMed search for "nicotinamide adenine dinucleotide" combined with intranasal or nasal, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature on raising NAD+ concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The second place the hedge disappears. "Intranasal NAD+ FOR cellular energy, mental clarity, and recovery" states three purposes for a preparation with no completed human trial of any kind — not by this route, and not for a cognitive endpoint by any route. NAD+ is genuinely central to cellular energy metabolism as biochemistry, which is what makes the sentence read plausibly; what has never been established is that spraying it up the nose changes how a person feels or thinks. To telos rx's credit the product page still carries the not-FDA-approved and approval-not-guaranteed language, and it does not claim a magnitude or a timeline.9
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim matches the trials
“PT-141 (bremelanotide) is a melanocortin peptide that works through the brain's arousal pathways rather than the vascular system, addressing desire at its source. It is studied for low sexual desire in women, including hypoactive sexual desire disorder (HSDD). Telos RX prescribes compounded PT-141 through a licensed US pharmacy, with ongoing access to a board-certified medical team.”
Read on the telos rx site, August 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Bremelanotide in premenopausal women with hypoactive sexual desire disorder — exactly the population telos rx names.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The second registration trial, same population.
This is the only correct statement of PT-141's evidence found anywhere in this review series, and it deserves to be said plainly. telos rx writes that bremelanotide "is studied for low sexual desire in WOMEN, including hypoactive sexual desire disorder (HSDD)" — which is precisely what RECONNECT 1 and 2 tested in 723 and 714 premenopausal women, and precisely what the approved product's label covers. Three other sellers in this market sell the same molecule to men for performance, against a label whose Limitations of Use say it is not indicated in men and not indicated to enhance sexual performance. The mechanism sentence is also right: it is a melanocortin agonist acting centrally rather than on blood flow. One reservation, and it is real: telos rx offers a "Get started (Men)" path alongside the women's one, so the page states the correct evidence and then sells beyond it.10,11
5-Amino-1MQ Injection (2 mg/mL)5-Amino-1MQ · Compounded (503A)Claim matches the trials
“5-Amino-1MQ blocks an enzyme called NNMT, which is involved in how cells handle energy and fat. It is studied for its role in metabolism. It is not a stimulant and does not replace diet, activity, or sleep. telos rx compounds it as a research peptide, and it is not FDA-approved. A licensed provider reviews your intake and decides whether it fits you.”
Read on the telos rx site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search returns ZERO records for "5-amino-1MQ" and zero for "5-amino-1-methylquinolinium" — not merely zero naming it as the intervention, but zero results of any kind. In PubMed the two terms together appear in 3 records, and ZERO carry the randomized-controlled-trial publication type. The same searches, run in the same pass, return 158 registry records and 126 trial papers for tirzepatide, so they discriminate. The NNMT mechanism telos rx describes is real and is drawn from preclinical work in cells and mice; no human trial of this molecule has been registered.
Graded as matching on a narrow but genuine reading, and the reasoning matters. Every factual assertion is true: 5-Amino-1MQ does inhibit NNMT, that enzyme is involved in cellular energy and fat handling, and the molecule is "studied for" its role in metabolism — in preclinical work, which is study. telos rx then volunteers two things almost nobody volunteers: that it "is not a stimulant" and that it "does not replace diet, activity, or sleep" — a negative claim about its own product. The reservation is severe and belongs beside that credit: there is no registered human trial of this molecule at all, anywhere, and no randomized-trial publication. A buyer reading "studied for its role in metabolism" would not learn that every study behind it is in cells and animals.12
Semax / Selank Nootropic StackSemax and Selank · Compounded (503A)Claim reaches past the trials
“Semax is studied for attention, mental clarity, and BDNF, a protein involved in neuron signaling. Selank is studied for stress and anxiety pathways tied to GABA and serotonin. telos rx combines both into one protocol. Both are compounded research peptides, and neither is FDA-approved. A licensed provider reviews your intake.”
Read on the telos rx site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search returns ZERO records naming Semax as an intervention and ZERO naming Selank — the two records a "selank" search returns are transcranial-stimulation studies that name neither. The published literature is not empty, and the distinction matters: PubMed holds 207 records mentioning Semax, of which ONE carries the randomized-controlled-trial publication type — a 2007 Russian-language paper in Zhurnal nevrologii i psikhiatrii on MOTOR NEURON DISEASE, not attention or cognition. It holds 68 mentioning Selank, of which TWO are randomized trials, both in the same Russian journal (2008 and 2015) and both in ANXIETY DISORDERS. The controls fired in the same pass: tirzepatide returned 126 randomized-trial papers.
The two halves of this stack deserve different verdicts, and the page gives them the same one. SELANK's claim is the better supported: "studied for stress and anxiety pathways" is backed by two randomized trials in generalized anxiety disorder, small and Russian-language but real and on point. SEMAX's is not: "studied for attention, mental clarity" rests on a single randomized trial that studied motor neuron disease, an entirely different question. Neither compound has a ClinicalTrials.gov record naming it as an intervention. Graded as reaching past the trials because the page presents both molecules as equivalently "studied" for the outcomes it names, when only one of them is.13
Dispensing chain
Who actually fills your prescription
- VialsRX — 6220 Westpark Dr, Houston, TX 77057
- F&F Pharmacies Inc dba Jungle Jim's Pharmacy — 5484 Dixie Highway, Fairfield, OH 45014
Read the full account
telos rx names both dispensing pharmacies with street addresses and phone numbers, in a product-page FAQ rather than buried in terms: "Your prescriptions are fulfilled by our partner compounding pharmacy, VialsRX… 6220 Westpark Dr, Houston, TX 77057 · (713) 497-5590 · vials.ai. We also partner with F&F Pharmacies Inc dba Jungle Jim's Pharmacy, located at 5484 Dixie Highway, Fairfield, OH 45014… (877) 858-3784." It also names the clinical entity separately, with its own office and compliance contact: Arora Health & Aesthetics, LLC, 300 Lenora Street, Seattle, WA 98121, arora-health.com. The most interesting disclosure on the site is a limitation it volunteers about its own supplier: of Jungle Jim's it writes that they "are able to dispense medications and maintain a license in 40 US states. Unfortunately, THEY CANNOT DISPENSE STERILE COMPOUNDS and do not have a license in the following US states: California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia, and Delaware." Nearly everything telos rx sells is a sterile injectable, so one of its two named pharmacies cannot make most of the catalog — and telos rx is the party that told you. That is candor, not concealment, and it is the reason a reader can reason about this supply chain at all. What remains unstated: which pharmacy fills a given order, and the regulatory category — "503A" and "503B" appear zero times on the site, which for a company this careful is a conspicuous gap. VialsRX is also the named pharmacy of another brand reviewed on this site; a shared pharmacy is not grounds to treat two companies as duplicates. And VialsRX is a different name from the "Vitals RX" that appears in FDA's warning-letter files — nothing here rests on the resemblance.
Read on the telos rx site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product — the same gap as every other company we've reviewed, and the one substantial thing missing from an otherwise unusually transparent site. What telos rx publishes instead is better than a testing slogan and worse than a document: two named pharmacies with street addresses and phone numbers, so a patient has somebody specific to ask; a named clinical entity with a compliance email; and, on every product page, the sentence "Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed." It never states its regulatory category — "503A" and "503B" each appear zero times — so a reader cannot tell whether the sterile injectables are made under 503A patient-specific compounding or by a registered outsourcing facility. Given that one named pharmacy is disclosed as unable to dispense sterile compounds at all, that is the single question a careful buyer would most want answered. Note also that telos rx cites no study, trial identifier or publication anywhere, for any product — its "studied for" formula is never attached to a named study a reader could check.
Read on the telos rx site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
All 50 states claimed, with formulation availability varying by state and disclosed as doing so
Read the full licensing claim
telos rx answers the coverage question directly and then, unusually, explains the caveat instead of hiding it. "Are these services available in my state? Yes. Services are available in all 50 US states through our affiliated medical providers and pharmacy partners. All operations strictly adhere to applicable state licensure requirements." It then asks and answers the follow-up almost nobody publishes: "Why does medication selection vary by location? Certain medications, specific formulations, or fulfillment options may vary. This is due to state-specific pharmacy regulations and local dispensing restrictions that our partners must follow." That is backed by a concrete disclosure — one of its two pharmacies is licensed in 40 states and not in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia or Delaware, and cannot dispense sterile compounds at all. No excluded state is recorded here because telos rx excludes none outright; what varies is which pharmacy and which formulation. Medical services are provided by Arora Health & Aesthetics, LLC (Seattle, WA), named with a compliance email and a website, while telos rx describes itself as "a technology and administrative services platform". No individual clinician is named and no license number is published. The corporate entity is Superior Health Solutions LLC.
Read on the telos rx site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with telos rx
We went through telos rx’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Pick one of four goals on the home page. GLP-1 weight loss is one of them.
- Press "Start your intake".
- Say what you want out of treatment, from a short list.
- Enter your weight, height, goal weight and how fast you want to get there.
- Enter your date of birth.
- Say whether you are male or female.
- Enter a phone number and a ZIP code.
- Work through several screens of medical history — conditions, past GLP-1 use, other medications.
- Enter an email address and create an account. The visit will not go further without one.
- Four weight-loss prices are public before you answer anything: as low as $139 a month for tirzepatide, $99 for semaglutide, from $9 a day for the oral version, and a fourth figure for microdosed tirzepatide on the same page.
- Every one of those is an "as low as" figure. telos rx says your price depends on plan length, and it publishes no month-to-month figure for any of them.
- Its own comparison table sets all four side by side in one row labeled "As low as" — and quotes three of them by the month and one by the day, so the row does not compare like with like.
- The visit asks for your phone number and ZIP code before it asks anything about your health.
- Roughly a third of the way through, the visit stops and asks for an email and an account. No price has appeared inside the visit by then, and that is where this walk ended.
- The same page that carries the prices says all four are compounded, not FDA-approved, and that a licensed provider has to approve the prescription.
telos rx support
- contact@telosrx.com
Assessment
What holds up, and what does not
- Its BPC-157 FAQ refuses the easiest sale on the site: "Will BPC-157 heal a specific injury or condition? We cannot say that… we make no promises about outcomes." No other seller we've reviewed answers its own best commercial question that way.
- Nearly every claim uses "studied for" rather than asserting an effect — a formula that is literally accurate for compounds whose evidence is preclinical or still recruiting.
- "Not FDA-approved" appears on every product page (23 occurrences site-wide), alongside "approval is not guaranteed" and "individual results vary".
Show 9 more
- It states PT-141's evidence correctly — "studied for low sexual desire in women, including hypoactive sexual desire disorder" — where three other sellers in this market sell the same molecule to men for performance against a label that excludes both.
- Both dispensing pharmacies are named with street addresses and phone numbers: VialsRX in Houston and Jungle Jim's Pharmacy in Fairfield, Ohio.
- It volunteers a limitation of its own supplier — that Jungle Jim's "cannot dispense sterile compounds" and lacks a license in ten named states — which is information against its own interest.
- The clinical entity is named separately with its own office, website and compliance email: Arora Health & Aesthetics, LLC, Seattle.
- Its 5-Amino-1MQ page states that the product "is not a stimulant and does not replace diet, activity, or sleep" — a negative claim about its own product.
- It explains why medication availability varies by state rather than claiming uniform nationwide service and leaving the exceptions undisclosed.
- The PT-141 "less than $5 a day" figure carries a footnote that actually resolves: "*Based on the 12-month plan."
- Struck-through reference prices are presented correctly, with the live price shown larger and the old price visibly crossed out.
- No FDA warning letter for telos rx or Superior Health Solutions LLC as of 10 August 2026.
- Sermorelin, at $125 a month, has no ClinicalTrials.gov record naming it as an intervention, and its 19 randomized trials are 1986-2005 pituitary pharmacology — and its nav line drops the site's usual hedge, selling it "for recovery, lean muscle, and sleep".
- 5-Amino-1MQ has zero registry records of any kind and zero randomized-trial publications; every study behind it is in cells and animals, which the page does not say.
- GHK-Cu's only registered trial is a TOPICAL GEL for skin wounds. telos rx sells a subcutaneous injection, and the page does not mark the difference.
Show 10 more
- The CJC-1295 record it rests on was TERMINATED, in HIV patients with visceral obesity — neither fact appears on the page.
- TB-500's only trial is measuring cardiovascular biomarkers in atherosclerotic disease, not the tissue repair the stack page implies.
- The Semax/Selank page presents both molecules as equivalently studied. Selank has two randomized trials in anxiety; Semax's single randomized trial studied motor neuron disease, not attention.
- The NAD+ nasal spray line — "for cellular energy, mental clarity, and recovery" — drops the hedge for a preparation with no completed human trial by any route.
- No certificate of analysis, lot number, potency or sterility result is published for any product.
- It never states its regulatory category: "503A" and "503B" appear zero times, which matters more here because one named pharmacy cannot dispense sterile compounds.
- No study, trial identifier or publication is cited anywhere — "studied for" is never attached to a study a reader can check.
- Headline prices are plan-length rates: "your price depends on plan length" is disclosed, but no month-to-month figure is published for any product.
- Several products — CJC-1295/ipamorelin, GHK-Cu, 5-Amino-1MQ, Semax/Selank — render no price at all on the product page.
- It states PT-141's evidence is in women and then offers a "Get started (Men)" path from the same page.
Verdict
The bottom line
Read "studied for" as exactly what it says. Across most of this catalog it means studied in cells, in animals, or in a trial that never finished — so go product by product and ask whether a completed human trial exists, and whether it used the route you are buying. For GHK-Cu the answer is no on both counts: the only registered trial is a topical gel, and the product is an injection.
Opens telosrx.com. A link is not a recommendation to take anything.
"We cannot say that"
Somewhere in the FAQ on telos rx's BPC-157 page is a question every buyer of that peptide actually has:
"Will BPC-157 heal a specific injury or condition?"
Here is the whole answer:
"We cannot say that. BPC-157 is not approved to treat, cure, or prevent any disease or injury, and we make no promises about outcomes. People use it to support general recovery goals, and individual results vary. For a specific medical condition, talk with your provider."
Across ten companies and dozens of product pages in this review series, no other seller has answered its own most commercially valuable question by declining to make the claim.
It is not an isolated flourish. The pattern runs through the site. Every peptide is "studied for" something rather than described as doing it. "Not FDA-approved" appears on every product page — 23 times across the pages fetched. So do "approval is not guaranteed" and "individual results vary". The 5-Amino-1MQ page volunteers that the product "is not a stimulant and does not replace diet, activity, or sleep" — a negative claim about its own product, which almost nobody writes.
This review is therefore an unusual shape. The problem with telos rx is not what it says. It is what it is selling.
Full analysis — 6 more sectionsThe catalog · Where the hedge slips · The one thing everybody else gets wrong · The pharmacy disclosure, including the part against its own interest · What you will pay · What this means if you are buying
The catalog
telos rx has the deepest peptide range of any company reviewed on this site: BPC-157, a BPC-157/TB-500 stack, CJC-1295/ipamorelin, GHK-Cu, MOTS-c, Semax/Selank, 5-Amino-1MQ, sermorelin, an NAD+ nasal spray, and PT-141 — plus four GLP-1 variants.
Here is what the registry actually holds for each.
| Product | Registry position |
|---|---|
| BPC-157 | one phase 2 recruiting (hamstring strain), one phase 1 n=42, status Unknown |
| TB-500 | one phase 1/2 recruiting — for cardiovascular biomarkers, not repair |
| CJC-1295 | one phase 2, TERMINATED, in HIV patients with visceral obesity |
| GHK-Cu | one phase 2 recruiting — of a TOPICAL GEL |
| MOTS-c | one phase 2 recruiting, insulin sensitivity in prediabetes |
| Sermorelin | nothing |
| NAD+ (intranasal) | nothing |
| 5-Amino-1MQ | nothing |
| Semax | 0 registry; 1 randomized paper — on motor neuron disease |
| Selank | 0 registry; 2 randomized papers — on anxiety |
| PT-141 | two phase 3 trials, 723 and 714 participants |
Two of those rows deserve their own paragraph.
GHK-Cu. The only registered trial of GHK-Cu is CuHeal — a phase 2 study of a topical gel applied to acute skin wounds, still recruiting. 5 telos rx sells a 10 mg/mL subcutaneous injection. A gel on a wound and an injection under the skin are different exposures with different distribution; a trial of one is not evidence for the other. The page describes the molecule accurately and never marks the route difference.
CJC-1295. The only registry record naming it is a phase 2 trial that was terminated, enrolling 120 HIV patients with visceral obesity. 4 Neither the termination nor the population appears on the page. (This corrects a record previously published on this site as "Completed" — it was re-read live from the registry on 10 August 2026.)
Where the hedge slips
The "studied for" formula is doing honest work almost everywhere. There are two places it disappears, and both are on the products with the least behind them.
Sermorelin, at $125 a month, is sold in the navigation as a "GHRH peptide that stimulates your own growth hormone for recovery, lean muscle, and sleep." Three outcomes, stated as purposes the drug serves.
Sermorelin has a human trial record, and it is not the one being sold. A ClinicalTrials.gov search returns no interventional record naming it, across six different searches including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass. 7 The 27 studies returned are other molecules. PubMed holds 24 mentions in titles and abstracts with zero trial publication types — but drop that restriction, which hides the molecule under its trial-literature name GHRH(1-29)-NH₂, and it returns 19 randomized controlled trials from 1986 to 2005, on growth-hormone stimulation and growth in children with GH deficiency. 8 None touches recovery, sleep, body composition or aging. All 19 predate mandatory trial registration, which is why the registry is bare. The same searches, run for tirzepatide, tesamorelin and bremelanotide, returned 158, 17 and 10 records — so the empty result is real, not a broken search.
NAD+ nasal spray, at $116 a month, is sold as "Intranasal NAD+ for cellular energy, mental clarity, and recovery." No completed human trial of intranasal NAD+ exists, and no registered study measures a cognitive endpoint for NAD+ by any route. 9 The real human literature is about oral precursors — different molecules, different route.
5-Amino-1MQ keeps the hedge and still needs a caveat the page does not give. Its claim — that it "blocks an enzyme called NNMT" and is "studied for its role in metabolism" — is entirely true. What a reader is not told is that a ClinicalTrials.gov search returns zero records of any kind for the molecule, under either name, and PubMed holds three mentions and no randomized trials. 12 Every study behind it is in cells and mice. "Studied" is accurate; "studied in humans" would not be.
Semax and Selank are sold as one stack and are not in the same evidential position. Selank's claim — "studied for stress and anxiety pathways" — is supported by two randomized trials in generalized anxiety disorder, small and Russian-language but real and on point. Semax's claim of "attention, mental clarity" rests on a single randomized trial that studied motor neuron disease. 13 The page presents both as equivalently studied.
The one thing everybody else gets wrong
Three companies in this review series sell PT-141 to men for sexual performance. The approved product containing that molecule is Vyleesi, and its label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." 11
telos rx's PT-141 page says this:
"It is studied for low sexual desire in women, including hypoactive sexual desire disorder (HSDD)."
That is exactly right. RECONNECT 1 and 2 enrolled 723 and 714 premenopausal women with HSDD. 10 It is the only accurate statement of this molecule's evidence found anywhere in this series, and it is worth crediting loudly.
The page then offers a "Get started (Men)" button alongside the women's one. So telos rx states the correct evidence and sells past it — which is still a better position than stating the wrong evidence, and is not nothing.
The pharmacy disclosure, including the part against its own interest
telos rx names both dispensing pharmacies, with street addresses and phone numbers, in a product-page FAQ:
"Your prescriptions are fulfilled by our partner compounding pharmacy, VialsRX… 6220 Westpark Dr, Houston, TX 77057 · (713) 497-5590 · vials.ai. We also partner with F&F Pharmacies Inc dba Jungle Jim's Pharmacy, located at 5484 Dixie Highway, Fairfield, OH 45014 · (877) 858-3784."
And then it says this about its own supplier:
"They are able to dispense medications and maintain a license in 40 US states. Unfortunately, they cannot dispense sterile compounds and do not have a license in the following US states: California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia, and Delaware."
Nearly everything telos rx sells is a sterile injectable. One of its two named pharmacies cannot make most of the catalog — and telos rx is the party that told you, unprompted, on a product page.
The clinical side is named separately and just as specifically: Arora Health & Aesthetics, LLC, 300 Lenora Street, Seattle, WA 98121, with a compliance email and a website. telos rx describes itself as "a technology and administrative services platform", with medical services provided by an independent medical group. The corporate entity is Superior Health Solutions LLC.
What is still missing is the regulatory category. "503A" and "503B" appear zero times on the site. For a company this careful that is a conspicuous gap, and given that one named pharmacy is disclosed as unable to dispense sterile compounds at all, it is the single question a careful buyer would most want answered.
And there is no certificate of analysis, no lot number, no potency or sterility result, for any product — the same gap as every other company here.
What you will pay
Headline prices are plan-length rates, and telos rx says so: "Your price depends on plan length. Cancel anytime, no penalties."
| Product | Advertised | Struck-through |
|---|---|---|
| BPC-157 | $116/mo | $189 |
| BPC-157 / TB-500 | $133/mo | — |
| MOTS-c | $116/mo | — |
| NAD+ nasal spray | $116/mo | $249 |
| Sermorelin | $125/mo | $299 |
| PT-141 | "less than $5 a day" | *based on the 12-month plan |
Two things done right that competitors get wrong. The struck-through prices are presented correctly — the crossed-out figure is visibly crossed out and the live price is the larger one, where another company we've reviewed advertises its struck-through number as the starting price. And the PT-141 asterisk actually resolves, to "*Based on the 12-month plan", where another company's asterisk in this series leads nowhere.
What is not published is any month-to-month figure, for any product. And four products — CJC-1295/ipamorelin, GHK-Cu, 5-Amino-1MQ and Semax/Selank — render no price on the page at all.
What this means if you are buying
If you want a company that will tell you who compounds your medication, what it can and cannot make, who the doctors are, and that it cannot promise the thing you came for — telos rx is the best answer among the sellers we've reviewed, and it isn't close.
Buy with the evidence in front of you, because telos rx will not overstate it and will not spell it out either. PT-141 has real phase 3 evidence, in women with HSDD. MOTS-c and BPC-157 have phase 2 trials that are still recruiting — meaning no result exists yet. GHK-Cu's trial is a topical gel and you would be buying an injection. CJC-1295's was terminated. TB-500's is about cardiovascular biomarkers. 5-Amino-1MQ and intranasal NAD+ have no human trial at all. Sermorelin has nineteen, all from 1986 to 2005 and all about pituitary function, none about what it is sold for here.
"Studied for" is an honest phrase, and for most of this catalog it means studied in cells, in animals, or in a trial that has not finished enrolling.
Questions
Frequently asked questions
Is telos rx selling research-use-only peptides?
No, despite calling them "research peptides". That phrase describes the stage of the evidence, not the regulatory category, and the distinction is the one this site cares most about. Across the pages fetched, "research use only" appears zero times, as do "no prescription", "not for human" and "laboratory use". What does appear is "licensed US pharmacy" 18 times, "licensed provider reviews" 11 times, "prescribed after provider review" 3 times, and "not FDA-approved" 23 times. Every product is compounded by a named US pharmacy and dispensed on a prescription after a clinician reviews an intake and may decline. That is a compounded prescription pathway, not gray-market material sold without a prescription. One thing telos rx never states is which compounding category applies — "503A" and "503B" appear zero times on the site.
Which peptides that telos rx sells actually have human trials?
One has strong evidence and the rest range from thin to none. PT-141 has two completed phase 3 trials, RECONNECT 1 and 2, in 723 and 714 premenopausal women with hypoactive sexual desire disorder. BPC-157 has a phase 2 trial recruiting for hamstring strain and a 42-person phase 1 whose registry status is Unknown. MOTS-c has one phase 2 recruiting for insulin sensitivity in prediabetes. TB-500 has one phase 1/2 recruiting — for cardiovascular biomarkers, not repair. CJC-1295's single record is a terminated phase 2 in HIV patients with visceral obesity. GHK-Cu's only trial is of a topical gel, while telos rx sells an injection. Semax has one randomized paper (on motor neuron disease) and Selank two (on anxiety), all in one Russian journal, with no ClinicalTrials.gov record for either. And 5-Amino-1MQ and intranasal NAD+ have no human trial record at all, while sermorelin's nineteen randomized trials are 1986-2005 pituitary pharmacology, none of it about recovery or aging. "Recruiting" means no result exists yet.
Does telos rx say which pharmacy fills my prescription?
It names both, with street addresses and phone numbers, which very little in this category does: VialsRX at 6220 Westpark Dr, Houston, TX 77057, (713) 497-5590; and F&F Pharmacies Inc dba Jungle Jim's Pharmacy at 5484 Dixie Highway, Fairfield, OH 45014, (877) 858-3784. It also names the clinical entity separately — Arora Health & Aesthetics, LLC, 300 Lenora Street, Seattle — with a compliance email. What it does not say is which of the two fills your specific order. It does, however, volunteer something against its own interest: Jungle Jim's is "able to dispense medications and maintain a license in 40 US states" but "cannot dispense sterile compounds" and lacks a license in ten named states. Nearly everything telos rx sells is a sterile injectable, so one of its two pharmacies cannot make most of the catalog — and telos rx is the party that told you.
Is telos rx right that PT-141 is for women?
Yes, and it is the only seller in this review series to say so. Its page reads: "It is studied for low sexual desire in women, including hypoactive sexual desire disorder (HSDD)." That matches the evidence exactly — bremelanotide's two phase 3 trials, RECONNECT 1 and 2, enrolled 723 and 714 premenopausal women with HSDD — and it matches the approved product's label, which carries two consecutive Limitations of Use stating that Vyleesi is not indicated in men and not indicated to enhance sexual performance. Three other companies we've reviewed sell the same molecule to men for exactly that. One reservation: telos rx offers a "Get started (Men)" path from the same page, so it states the correct evidence and then sells beyond it.
What does telos rx cost?
The advertised figures are plan-length rates and the site says so — "Your price depends on plan length. Cancel anytime, no penalties." BPC-157 is "as low as $116 per month" with $189 struck through; the BPC-157/TB-500 stack $133; MOTS-c $116; NAD+ nasal spray $116 with $249 struck through; sermorelin $125 with $299 struck through. PT-141 is advertised as "less than $5 a day", with an asterisk that actually resolves — "*Based on the 12-month plan." Two things done properly: the struck-through prices are presented correctly, with the crossed-out number visibly crossed out and the live price larger, where a rival we've reviewed advertises its struck-through figure as the starting price. What is not published is a month-to-month rate for anything, and four products — CJC-1295/ipamorelin, GHK-Cu, 5-Amino-1MQ and Semax/Selank — show no price on the page at all.
Does telos rx publish test results?
No. There is no certificate of analysis, lot number, potency result, sterility result or named laboratory anywhere on the site — the same gap as every company in this market. What it offers instead is the ability to ask somebody: two pharmacies named with addresses and phone numbers, and a clinical entity with a compliance email. The site also carries, on every product page, "Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed." Two things are missing that matter more here than usual. It never states its compounding category — "503A" and "503B" appear zero times — which is the natural question once one of its named pharmacies is disclosed as unable to dispense sterile compounds. And it cites no study, trial identifier or publication anywhere, so its "studied for" formula is never attached to a study a reader can check.
Glossary
Key terms
Show definitions
- "Studied for"
- telos rx's house formula. It is literally accurate and deliberately weaker than "shown to" — but it does not distinguish a completed phase 3 trial from a mouse study or a trial that is still enrolling. For most of this catalog it means the latter.
- Recruiting
- A registry status meaning a trial is still enrolling participants. It has produced no result. Four of telos rx's peptides rest on trials at this status.
- Terminated
- A trial stopped before completion. Materially weaker than "completed", and the status of the only registry record for CJC-1295.
- Sterile compound
- A preparation made under sterile conditions for injection. Compounding one requires specific facilities and licensure. telos rx discloses that one of its two named pharmacies cannot make them.
Compare
Others selling what telos rx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off telos rx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 13 sources
- US National Library of Medicine (2026). BPC-HAMSTR — BPC 157 for Acute Hamstring Muscle Strain Repair, phase 2, recruiting, n=120, NCT07437547. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437547
- US National Library of Medicine (2026). PCO-02 — Safety and Pharmacokinetics Trial of Bepecin (BPC-157), phase 1, status Unknown, n=42, NCT02637284. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). TBRIDGE-CV — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD, phase 1/2, recruiting, n=80, NCT07487363. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07487363
- US National Library of Medicine (2026). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity — phase 2, TERMINATED, n=120, NCT00267527. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00267527
- US National Library of Medicine (2026). CuHeal — Topical GHK-Cu Gel for Acute Skin Wound Healing, phase 2, recruiting, n=60, NCT07437586. That's a topical gel, not an injection. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). MOTS-MET — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, phase 2, recruiting, n=120, NCT07505745. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six separate searches plus a free-text pass. The same pass returned 158 records for tirzepatide, 17 for tesamorelin and 10 for bremelanotide. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] returns 19 records, published 1986-2005. Restricting the same query to title and abstract returns 0, because the trial literature names the molecule GHRH(1-29)-NH2 rather than sermorelin. Re-run 2026-08-12 with a fabricated-molecule negative control returning 0.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for intranasal and injected NAD+ in humans: no completed randomised trial, and no registered study measuring a cognitive endpoint for NAD+ by any route. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). RECONNECT Study 1 (NCT02333071, phase 3, completed, n=723) and RECONNECT Study 2 (NCT02338960, phase 3, completed, n=714) — bremelanotide in premenopausal women with hypoactive sexual desire disorder. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02333071
- US Food and Drug Administration (2026). VYLEESI (bremelanotide) injection — prescribing information, section 1, Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." Read 2026-08-10.. FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- US National Library of Medicine (2026). ClinicalTrials.gov v2 intervention searches for "5-amino-1MQ" and "5-amino-1-methylquinolinium" return ZERO records of any kind. PubMed holds 3 records mentioning either term and 0 with the randomised-controlled-trial publication type. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=5-amino-1MQ
- US National Library of Medicine (2026). Semax and Selank: ClinicalTrials.gov returns no record naming either as an intervention. PubMed holds 207 records mentioning Semax, of which 1 is a randomised controlled trial (PMID 18379501, motor neuron disease, Zhurnal nevrologii i psikhiatrii, 2007); and 68 mentioning Selank, of which 2 are randomised controlled trials (PMIDs 18454096 and 26356395, generalised anxiety disorder, same journal, 2008 and 2015). Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=selank%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.